Cidofovir

Cidofovir is a powerful broad-spectrum antiviral medication that has become an important therapeutic option for treating ocular infections caused by feline herpesvirus type 1 (FHV-1) in cats. Originally developed as a human antiviral medication for treating cytomegalovirus infections in immunocompromised patients, cidofovir has been adapted for veterinary use as a compounded ophthalmic solution. The medication belongs to the nucleotide analog class of antivirals and has demonstrated significant efficacy against FHV-1, which is one of the most common causes of ocular disease in cats worldwide. Veterinary ophthalmologists and general practitioners increasingly rely on cidofovir as a first-line topical treatment for herpetic eye disease in feline patients due to its proven effectiveness and convenient dosing schedule.

Cidofovir works through a unique mechanism that distinguishes it from many other antiviral medications used in feline medicine. As a nucleotide analog, cidofovir is incorporated into the viral DNA during replication, which causes premature chain termination and prevents the virus from successfully multiplying. Unlike some other antivirals that require viral enzymes for activation, cidofovir is phosphorylated by cellular enzymes rather than viral thymidine kinase, which makes it effective even against some viral strains that might be resistant to other antiviral agents. The medication has a prolonged intracellular half-life, which allows for less frequent dosing compared to other topical ophthalmic antivirals while maintaining therapeutic concentrations at the site of infection.

For feline patients, cidofovir is available exclusively as a compounded ophthalmic solution, typically prepared at a concentration of 0.5 percent. This formulation is applied directly to the affected eye or eyes as drops, making it a targeted local treatment that minimizes systemic absorption and associated risks. One of the significant advantages of cidofovir over other topical antivirals is its twice-daily dosing requirement, which is considerably less frequent than medications like trifluridine or idoxuridine that require administration four to six times daily. This more convenient dosing schedule improves owner compliance and reduces stress for both cats and their caregivers, as frequent eye drop administration can be challenging with feline patients.

Cidofovir has demonstrated a favorable safety profile when used topically in cats, with most feline patients tolerating the medication well throughout their treatment course. However, it remains a prescription medication that should only be used under veterinary supervision, as proper diagnosis of herpetic disease is essential before initiating antiviral therapy. The medication is not FDA-approved for veterinary use and must be obtained through compounding pharmacies that prepare the ophthalmic solution according to veterinary prescriptions. Cat owners should understand that while cidofovir effectively reduces viral replication and improves clinical signs, it does not cure herpesvirus infection, as FHV-1 establishes lifelong latency in infected cats. Completing the full prescribed treatment course is important to maximize therapeutic benefit and reduce the risk of disease recurrence.

The primary indication for cidofovir in cats is the treatment of ocular surface disease caused by feline herpesvirus type 1 (FHV-1), which represents one of the most common infectious causes of eye problems in the feline population. FHV-1 is an alpha-herpesvirus that specifically targets the epithelial tissues of the eyes, respiratory tract, and occasionally the skin of cats. Ocular manifestations of FHV-1 infection are particularly prevalent and can range from mild conjunctivitis to severe corneal ulceration that threatens vision. Cidofovir has proven effective in reducing viral shedding and alleviating clinical signs associated with active herpetic eye disease, making it a valuable therapeutic tool for veterinary ophthalmologists and general practitioners managing these common feline conditions.

The most frequent application of cidofovir is in treating herpetic conjunctivitis, which presents as inflammation of the conjunctival membranes surrounding the eye. Affected cats typically display redness, swelling, and discharge from one or both eyes, often accompanied by squinting and apparent ocular discomfort. Clinical studies have demonstrated that twice-daily application of 0.5 percent cidofovir ophthalmic solution significantly decreases viral load and improves clinical scores in cats with FHV-1 conjunctivitis. The medication is particularly valuable in shelter environments where herpesvirus infection rates are high and rapid disease control is essential for both animal welfare and population management. Research has shown that cidofovir significantly decreased viral load from day one to day eight of treatment compared with placebo in shelter-housed cats with FHV-1 ocular disease.

Cidofovir is also indicated for treating herpetic keratitis, a more serious manifestation of FHV-1 infection that involves the cornea itself. Dendritic ulcers, which have a characteristic branching pattern, are pathognomonic for herpesvirus infection and represent a condition where cidofovir therapy is particularly appropriate. The medication helps control viral replication within the corneal epithelium, allowing the damaged tissue to heal while preventing further virus-mediated destruction. Cats with corneal sequestra, a condition where devitalized corneal tissue becomes brown or black and is strongly associated with FHV-1 infection, may also benefit from cidofovir therapy as part of their overall treatment plan. By reducing active viral replication, cidofovir can help prevent progression of corneal disease and support the healing process.

Beyond acute infections, cidofovir may be used in managing chronic or recurrent herpetic eye disease, which is common due to the lifelong latent infection that FHV-1 establishes in the trigeminal ganglia of infected cats. Stress, concurrent illness, or immunosuppression can trigger viral reactivation, leading to repeated episodes of ocular disease. Some veterinarians prescribe cidofovir for short courses during these flare-ups to control symptoms and reduce viral shedding. The medication may also be considered for cats with severe or frequently recurring disease who have not responded adequately to other treatments. Its unique mechanism of action, which does not depend on viral thymidine kinase for activation, means cidofovir may retain efficacy against viral strains that have become resistant to other antivirals.

Veterinarians choose cidofovir over alternative antiviral medications for several important reasons related to its pharmacological properties and practical advantages. The twice-daily dosing schedule is substantially more manageable than the four to six times daily administration required for older topical antivirals like trifluridine and idoxuridine. This improved convenience translates to better owner compliance and less stress for feline patients who often resent frequent eye drop administration. Additionally, cidofovir has demonstrated excellent in vitro activity against FHV-1 and has performed well in controlled clinical studies, providing veterinarians with evidence-based confidence in its therapeutic efficacy. The medication is particularly valuable when owners have limited availability for frequent dosing or when treating fractious cats where minimizing handling is desirable for both safety and animal welfare reasons.

The dosing protocol for cidofovir in cats follows well-established guidelines developed through clinical research and extensive practical experience in veterinary ophthalmology. As with all medications prescribed for cats, the specific treatment regimen should be determined by a veterinarian who has examined the patient and confirmed the diagnosis of herpetic eye disease. Cidofovir is administered as a compounded ophthalmic solution, typically prepared at a concentration of 0.5 percent, which has been shown to provide optimal efficacy while minimizing the risk of local irritation. The veterinarian will consider the severity of the ocular disease, the cat's overall health status, and any concurrent conditions when determining the appropriate treatment plan for each individual patient.

The standard dosing recommendation for cidofovir ophthalmic solution in cats is one drop applied to the affected eye or eyes twice daily. This twice-daily regimen takes advantage of cidofovir's prolonged intracellular half-life, which allows the medication to maintain therapeutic concentrations between doses. Clinical studies evaluating cidofovir efficacy have consistently used this twice-daily protocol with excellent results. The 0.5 percent concentration has become the standard formulation, as research has demonstrated that this strength provides effective antiviral activity while remaining well-tolerated by feline patients. Higher concentrations may cause increased ocular irritation without providing additional therapeutic benefit.

The typical treatment duration for cidofovir therapy ranges from seven to fourteen days, though some cases may require longer courses depending on clinical response and disease severity. Cats with mild conjunctivitis may show significant improvement within the first week of treatment, while those with more severe corneal involvement may need extended therapy. The veterinarian will schedule follow-up examinations to assess the cat's response to treatment and determine when medication can be discontinued. It is important to continue treatment for the full prescribed duration even if symptoms appear to resolve, as premature discontinuation may allow viral replication to resume and clinical signs to recur. Some cats with chronic or frequently recurrent disease may require intermittent treatment courses whenever flare-ups occur.

Proper administration technique is essential for maximizing the effectiveness of cidofovir eye drops while minimizing stress for both the cat and the caregiver. Before administering the medication, owners should wash their hands thoroughly and gently clean any discharge from around the cat's eye using a clean, damp cloth or cotton ball. The cat should be positioned comfortably, either on a stable surface or wrapped gently in a towel if needed to prevent struggling. To apply the drop, the lower eyelid is gently pulled down to create a small pocket, and one drop of the solution is placed into this pocket without touching the dropper tip to the eye or surrounding tissues. After administration, the cat should be allowed to blink naturally, which helps distribute the medication across the eye surface. Warming the dropper slightly in the hand before use can make the drops more comfortable and reduce the cat's reaction to cold solution.

If a dose of cidofovir is missed, owners should administer it as soon as they remember unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling up on doses to make up for a missed administration is never recommended, as this could increase the risk of local irritation without providing additional therapeutic benefit. Consistency in dosing times helps maintain steady medication levels at the site of infection, so owners should try to establish a regular routine that fits their daily schedule. If multiple doses are missed or the owner is having difficulty administering the medication, they should contact their veterinarian for guidance.

Completing the full course of cidofovir treatment as prescribed is crucial for achieving optimal therapeutic outcomes and reducing the likelihood of disease recurrence. Although clinical improvement may be apparent within the first few days of treatment, continuing the medication for the entire prescribed duration helps ensure that viral replication is adequately suppressed. Unlike bacterial infections where incomplete antibiotic courses can promote resistance, the concern with prematurely stopping antiviral therapy is primarily related to allowing active viral replication to resume, which can lead to renewed clinical signs and potentially more severe disease. Cat owners should maintain communication with their veterinarian throughout the treatment period and report any concerns about the cat's response to therapy or difficulties with medication administration.

Cidofovir ophthalmic solution is generally well-tolerated by cats when used as directed for the treatment of feline herpesvirus eye infections. The topical route of administration limits systemic absorption, which significantly reduces the risk of body-wide side effects that can occur with systemically administered antiviral medications. Most cats complete their treatment courses without experiencing any notable adverse reactions, particularly when the medication is compounded at the standard 0.5 percent concentration. However, as with any medication, some cats may experience side effects, and owners should be aware of what to watch for during treatment so they can report concerns to their veterinarian promptly.

The most commonly observed side effects of cidofovir eye drops in cats are mild local reactions at the site of application. Some cats may experience temporary burning, stinging, or discomfort immediately after the drops are administered, which typically manifests as increased blinking, squinting, or pawing at the eye. These reactions are usually brief, resolving within a few minutes as the medication disperses across the eye surface. Mild redness or irritation of the conjunctiva may also occur, though this can be difficult to distinguish from the underlying herpetic disease being treated. Solutions compounded at higher concentrations than the standard 0.5 percent may cause more pronounced irritation, which is why veterinarians typically prescribe the established concentration that balances efficacy with tolerability.

Less common side effects that have been reported with cidofovir use in cats include superficial keratitis and irritation of the nasolacrimal duct system. The nasolacrimal duct connects the eye to the nasal cavity, and some studies have noted that prolonged cidofovir use may cause changes to this structure. Clinical observations have suggested that cats should be monitored for signs of nasolacrimal dysfunction, though this appears to be an uncommon occurrence with typical treatment durations. Veterinary ophthalmologists recommend careful monitoring during extended treatment courses, and owners should report any changes in tear drainage or unusual nasal symptoms to their veterinarian. These effects generally appear mild when they do occur and may be reversible upon discontinuation of treatment.

Serious side effects from topically applied cidofovir are rare in cats, which is one of the medication's advantages over some systemically administered antivirals. The intravenous form of cidofovir used in human medicine is associated with significant kidney toxicity, but this concern does not apply to the small amounts absorbed from ophthalmic application. Nevertheless, cidofovir should be used with caution in cats with pre-existing kidney disease, as the feline kidney is particularly sensitive and renal dysfunction is common in the cat population, especially among older animals. Allergic reactions to cidofovir are possible though uncommon, and owners should watch for signs such as severe swelling, intense redness, or pronounced discomfort that persists beyond the expected brief post-application period.

Owners should contact their veterinarian if their cat experiences any unexpected reactions to cidofovir or if mild side effects persist or worsen over time. Signs that warrant prompt veterinary attention include severe or prolonged eye pain, significant changes in vision or behavior, development of new eye problems, or any systemic symptoms such as lethargy, decreased appetite, or vomiting. If any cidofovir solution remains on the cat's face after administration, it should be gently blotted away to prevent the cat from ingesting it during grooming and to avoid accidental exposure to other household members. While serious adverse events are uncommon with proper use, maintaining awareness of potential side effects allows for early intervention if problems develop and helps ensure the best possible outcome for cats undergoing treatment for herpetic eye disease.

Cidofovir ophthalmic solution should not be used in cats with known hypersensitivity or allergy to cidofovir or any components of the compounded formulation. Although true allergic reactions to cidofovir are uncommon, cats that have previously experienced adverse reactions to the medication should not receive it again. Signs of a potential allergic reaction may include severe eye swelling, intense redness extending beyond normal, hives or skin reactions, or respiratory distress. If a cat has had an allergic reaction to related nucleotide analog antiviral medications, caution should be exercised, as cross-reactivity is possible. Pet owners should inform their veterinarian of any previous medication reactions their cat has experienced before starting cidofovir therapy to ensure the safest possible treatment approach.

Cats with significant kidney disease require careful consideration before cidofovir is prescribed, even for topical ophthalmic use. While systemic absorption from eye drops is minimal, the intravenous form of cidofovir used in humans is known to cause serious nephrotoxicity, and residual concerns exist about any potential kidney effects from absorbed medication. Chronic kidney disease is extremely common in cats, particularly in middle-aged and senior felines, making this a relevant consideration for a substantial portion of the population that might benefit from antiviral therapy. Veterinarians may choose alternative antiviral agents for cats with known renal insufficiency or may recommend baseline kidney function testing before initiating therapy in older patients. If cidofovir is deemed the best treatment option for a cat with compromised kidney function, more frequent monitoring may be warranted.

The use of cidofovir in pregnant, nursing, or breeding cats warrants particular caution due to limited safety data in these populations. In human medicine, cidofovir is classified as a pregnancy risk category due to its mechanism of action affecting DNA synthesis, which theoretically poses risks to developing fetuses. While topical ophthalmic administration results in minimal systemic exposure compared to intravenous use, veterinarians generally recommend avoiding cidofovir in pregnant queens unless the benefits clearly outweigh potential risks. Nursing cats present similar concerns, as the extent to which cidofovir or its metabolites may be excreted in milk is not well established. Cats intended for breeding programs should ideally complete their breeding careers before receiving cidofovir, or alternative treatments should be considered when antiviral therapy is needed.

Cats with certain concurrent medical conditions may require modified approaches or alternative medications instead of cidofovir. Those with severe ocular surface disease involving extensive corneal perforation may need surgical intervention before topical medical therapy is appropriate. Immunocompromised cats, while potentially benefiting from antiviral treatment, require careful overall management that addresses their underlying immune dysfunction. Additionally, cidofovir should not be used in cats for conditions where herpesvirus has not been confirmed or reasonably suspected, as the medication has no activity against bacterial, fungal, or other non-viral causes of eye disease. Providing a complete medical history, including all current medications, supplements, and known health conditions, enables the veterinarian to determine whether cidofovir is appropriate and safe for each individual patient.

Pet owners should inform their veterinarian of all medications, supplements, and other treatments their cat is receiving before starting cidofovir therapy. Although cidofovir is administered topically to the eye with minimal systemic absorption, potential interactions can still occur, particularly with other ophthalmic medications that may be part of a comprehensive treatment plan for feline eye disease. Providing a complete medication history ensures that the veterinarian can anticipate and manage any potential interactions, adjust dosing schedules as needed, and monitor appropriately for any unexpected effects. This includes prescription medications, over-the-counter products, herbal supplements, and any other substances the cat receives regularly or intermittently.

The most clinically significant interaction affecting cidofovir efficacy involves concurrent use of topical ophthalmic corticosteroids. Corticosteroid eye drops such as prednisolone acetate or dexamethasone are sometimes prescribed for inflammatory eye conditions, but their use alongside antiviral therapy requires careful consideration. Corticosteroids suppress the local immune response, which can potentially allow viral replication to continue unchecked even in the presence of antiviral medication. Studies and clinical experience suggest that the antiviral activity of cidofovir may be reduced when topical corticosteroids are administered simultaneously. Veterinary ophthalmologists typically recommend avoiding concurrent use of these medications or, when anti-inflammatory therapy is necessary, carefully timing the administration to minimize interference with antiviral activity.

When multiple ophthalmic medications are prescribed, the timing and order of administration can affect their individual efficacy. If a cat requires both cidofovir and other eye drops or ointments, the veterinarian will provide specific instructions on the appropriate interval between medications. Generally, waiting at least five to ten minutes between different ophthalmic preparations allows each medication to be adequately absorbed before the next is applied. Eye ointments, if prescribed, are typically administered last because their thick consistency can create a barrier that prevents drops from reaching the eye surface. Following the veterinarian's instructions precisely ensures that each medication can work effectively without interference from other treatments.

While food and dietary interactions are not a significant concern for topically administered cidofovir, owners should be aware that some systemic medications their cat takes could theoretically affect cidofovir if absorption does occur. Probenecid, a medication used for certain conditions in both humans and occasionally animals, can affect the elimination of cidofovir and its related compounds. Although this interaction is primarily relevant for systemic cidofovir administration, veterinarians should be informed if a cat is receiving probenecid or other medications that affect renal tubular secretion. Nutritional supplements and herbal products are generally not expected to interact with topical cidofovir, but disclosure of all substances the cat receives allows the veterinarian to make fully informed treatment decisions.

General precautions for using cidofovir in cats begin with ensuring accurate diagnosis and appropriate case selection. The medication is specifically effective against viral infections and will not benefit cats with eye disease caused by bacteria, fungi, or other non-viral pathogens. Before initiating cidofovir therapy, veterinarians typically confirm or strongly suspect feline herpesvirus involvement based on clinical signs, history, and potentially diagnostic testing. Using antiviral medications inappropriately not only fails to help the patient but may delay appropriate treatment for the actual underlying condition. Owners should trust their veterinarian's diagnostic process and understand that cidofovir is prescribed based on specific indications rather than as a general treatment for all eye problems.

Variations in medication sensitivity among individual cats mean that monitoring during treatment is important for all patients. While cidofovir is generally well-tolerated, some cats may be more sensitive to the medication than others due to individual differences in physiology, concurrent health conditions, or genetic factors. Owners should observe their cat closely during the treatment period and report any unexpected reactions or concerning changes promptly. The veterinarian may schedule follow-up examinations to assess treatment response and watch for any adverse effects. Cats with a history of sensitive eyes or previous reactions to ophthalmic medications may warrant extra vigilance during cidofovir therapy.

Environmental and handling precautions help ensure safe use of cidofovir for both the cat and household members. The medication should be administered in a clean environment, and owners should wash their hands before and after handling the eye drops. Any medication that contacts surfaces outside the intended application area should be cleaned up promptly. In households with multiple cats, treated animals should be kept separate from untreated cats during active disease episodes to prevent viral transmission, as cidofovir reduces but does not eliminate viral shedding. Owners should avoid touching the dropper tip to any surface, including the cat's eye, to maintain sterility of the remaining solution. Protective measures such as wearing disposable gloves may be considered by owners who have concerns about medication exposure.

Ongoing monitoring during cidofovir treatment helps ensure optimal outcomes and early detection of any problems. Owners should watch for signs that the condition is improving, such as reduced redness, decreased discharge, improved comfort, and increased willingness to open the affected eye. Conversely, signs of worsening disease or lack of response to treatment warrant veterinary reassessment, as alternative diagnoses or treatments may need to be considered. The veterinarian may recommend periodic examinations during the treatment course, particularly for more severe cases or cats with a history of complicated ocular disease. Documentation of clinical progress through photographs can be helpful for tracking changes between veterinary visits.

Special populations including very young kittens, geriatric cats, and those with chronic health conditions may require modified approaches to cidofovir therapy. Kittens with developing immune systems are particularly susceptible to severe herpesvirus infections, and early treatment is important, though dosing considerations may differ from adult cats. Elderly cats commonly have concurrent kidney disease, making careful case selection and monitoring especially important in this age group. Immunocompromised cats, whether due to feline immunodeficiency virus infection, feline leukemia virus, or immunosuppressive medications, may experience more severe or prolonged herpesvirus episodes and may require longer treatment courses or combination therapy approaches. Veterinary guidance is essential for determining the most appropriate treatment strategy for cats in these special populations.

Proper storage of cidofovir ophthalmic solution is essential for maintaining medication stability and ensuring therapeutic efficacy throughout the treatment period. Because cidofovir for veterinary use is typically obtained as a compounded preparation, storage requirements may vary slightly depending on the compounding pharmacy's specific formulation. Generally, cidofovir ophthalmic solution should be stored in the refrigerator at temperatures between 36 and 46 degrees Fahrenheit (2 to 8 degrees Celsius), as cold storage helps preserve the medication's potency and prevent degradation. Research has shown that cidofovir 0.5 percent retains efficacy when compounded in normal saline and refrigerated for up to six months in either plastic or glass containers. Owners should check the label provided by the compounding pharmacy for specific storage instructions applicable to their particular preparation.

Protection from light and contamination are important considerations for maintaining cidofovir solution integrity. The dropper bottle should be kept tightly closed when not in use to prevent evaporation and microbial contamination. Some formulations may be dispensed in amber or opaque containers to protect the solution from light degradation. When removing the medication from the refrigerator for administration, owners should allow a few moments for the solution to approach room temperature or warm the dropper bottle briefly in their hands, as cold drops can cause discomfort when applied to the eye. However, the medication should be returned to the refrigerator promptly after use rather than left at room temperature for extended periods. The bottle tip should never contact any surface during use to maintain sterility.

Safe handling of cidofovir protects both household members and pets from unintended exposure. Adults should supervise administration and ensure the medication is stored in a location inaccessible to children and other animals. Any solution that contacts surfaces outside the eye should be cleaned up promptly, and hands should be washed thoroughly after administration. Used dropper bottles should be disposed of according to the compounding pharmacy's instructions or local pharmaceutical waste guidelines rather than discarded with regular household trash. Many veterinary clinics and pharmacies participate in medication take-back programs that provide safe disposal options for unused or expired veterinary medications. If the solution appears cloudy, discolored, or contains visible particles, it should not be used and should be replaced with a fresh preparation.

Cidofovir is generally well-tolerated across all cat breeds when used appropriately for the treatment of feline herpesvirus ocular infections. Unlike some medications that show significant breed-related variations in metabolism or sensitivity, cidofovir's topical ophthalmic administration results in minimal systemic absorption, which reduces the potential for breed-specific pharmacokinetic differences to influence treatment outcomes. The medication's local action at the site of application means that genetic variations in liver enzymes or other metabolic pathways have little impact on its efficacy or safety profile. Nevertheless, veterinarians consider each cat as an individual, and certain breed characteristics may influence treatment decisions or monitoring approaches.

Certain cat breeds may have anatomical features or predispositions that affect their experience with ophthalmic medications or their susceptibility to herpesvirus disease. Brachycephalic breeds such as Persians, Himalayans, and Exotic Shorthairs have shortened facial structures that can predispose them to chronic eye problems including corneal exposure, tear drainage abnormalities, and increased susceptibility to infections. These breeds may require more frequent monitoring during cidofovir treatment and may be more prone to developing complications from underlying ocular surface disease. Their prominent eyes and shallow orbits can make medication administration more challenging, and owners of brachycephalic cats should receive thorough instruction on proper drop application technique.

Breed size variations in cats, while less dramatic than in dogs, can still influence medication considerations. Large breed cats such as Maine Coons may have correspondingly larger eyes, though standard cidofovir drop volumes are typically adequate for all domestic cat breeds. Very small cats or those significantly underweight may theoretically absorb proportionally more medication systemically, though this is rarely a clinical concern with topical ophthalmic preparations. Kittens of any breed represent a special consideration due to their small size and developing organ systems. While cidofovir has been used successfully in juvenile cats with herpesvirus infections, veterinarians exercise appropriate caution and monitor young patients carefully during treatment.

Age-related considerations apply across all breeds and influence how cidofovir therapy is approached. Kittens are particularly susceptible to severe herpesvirus infections due to their immature immune systems, and shelters and catteries often see high rates of FHV-1 disease in young cat populations. Early and appropriate antiviral treatment can significantly improve outcomes for these vulnerable patients. Conversely, senior cats of any breed commonly have concurrent health conditions, particularly chronic kidney disease, which may influence treatment decisions. While topical cidofovir administration minimizes systemic exposure, veterinarians may recommend baseline blood work for older cats to assess kidney function before initiating therapy. Geriatric cats may also have reduced tear production or other age-related ocular changes that affect how medications distribute across the eye surface and integrate into comprehensive ophthalmic care plans.

Several other antiviral medications belong to the same therapeutic category as cidofovir and may be considered as alternatives or adjuncts for treating feline herpesvirus ocular infections. Trifluridine (Viroptic) is a topical ophthalmic antiviral that has been used for decades in veterinary medicine for FHV-1 keratitis and conjunctivitis. Unlike cidofovir's twice-daily dosing, trifluridine requires administration four to six times daily, which can be challenging for cat owners to maintain. Idoxuridine is another topical antiviral available as a compounded ophthalmic preparation that also requires frequent daily dosing. Ganciclovir ophthalmic gel represents a newer option that has shown some promise in treating herpetic eye disease in cats, though studies have produced mixed results regarding its efficacy compared to cidofovir. These alternative topical antivirals may be selected when cidofovir is unavailable, contraindicated, or when a cat has not responded adequately to initial therapy.

Famciclovir (Famvir) represents an important systemic antiviral option that works through a different administration route than cidofovir. Given orally, famciclovir is metabolized to penciclovir, which has demonstrated activity against FHV-1. Systemic administration allows famciclovir to address herpesvirus infection throughout the body, including respiratory and dermatologic manifestations that topical eye drops cannot reach. Veterinarians may prescribe famciclovir alone for cats with primarily respiratory or skin involvement, or in combination with topical cidofovir for comprehensive treatment of cats with both ocular and systemic disease. The combination approach provides localized high concentrations of antiviral medication at the eye surface while also delivering systemic antiviral activity that can help control overall viral burden.

Complementary therapies and supportive care often accompany antiviral treatment for cats with herpesvirus disease. L-lysine supplementation has been historically recommended based on the theory that it might interfere with viral replication, though more recent research has questioned its efficacy. Regardless, many veterinarians include nutritional support as part of comprehensive FHV-1 management. Artificial tear preparations help maintain ocular surface health and comfort during active disease. Cats with secondary bacterial infections may require concurrent antibiotic therapy, either topical or systemic depending on the severity and location of infection. The veterinarian will develop an individualized treatment plan based on the specific manifestations of disease in each patient. Cat owners should never substitute medications or make changes to treatment protocols without veterinary guidance, as inappropriate medication use can worsen disease or cause additional harm to the patient.